Insider Transactions in Q1 2022 at Phreesia, Inc. (PHR)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-0.04%
|
$1,404
$27.78 P/Share
|
|
Feb 18
2022
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
78,106
+3.02%
|
$468,636
$6.37 P/Share
|
|
Jan 31
2022
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
280
+0.96%
|
$8,680
$31.19 P/Share
|
|
Jan 31
2022
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
280
+1.88%
|
$8,680
$31.19 P/Share
|
|
Jan 21
2022
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+3.38%
|
$50,000
$2.03 P/Share
|
|
Jan 19
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,228
-0.86%
|
$71,296
$32.62 P/Share
|
|
Jan 17
2022
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,206
-3.27%
|
$1,372,210
$35.55 P/Share
|
|
Jan 17
2022
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,743
-0.25%
|
$61,005
$35.55 P/Share
|
|
Jan 17
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-0.19%
|
$14,560
$35.55 P/Share
|
|
Jan 17
2022
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
1,231
-1.08%
|
$43,085
$35.55 P/Share
|
|
Jan 17
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
501
-0.71%
|
$17,535
$35.55 P/Share
|
|
Jan 15
2022
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,438
-1.51%
|
$645,330
$35.55 P/Share
|
|
Jan 15
2022
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,543
-1.36%
|
$334,005
$35.55 P/Share
|
|
Jan 15
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
4,251
-1.89%
|
$148,785
$35.55 P/Share
|
|
Jan 15
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
849
-0.65%
|
$29,715
$35.55 P/Share
|
|
Jan 15
2022
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
879
-0.75%
|
$30,765
$35.55 P/Share
|
|
Jan 15
2022
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
4,211
-3.56%
|
$147,385
$35.55 P/Share
|
|
Jan 15
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,364
-3.22%
|
$82,740
$35.55 P/Share
|
|
Jan 14
2022
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,420
+6.98%
|
-
|
|
Jan 14
2022
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,445
+7.09%
|
-
|
|
Jan 14
2022
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
53,445
+19.21%
|
-
|
|
Jan 14
2022
|
Randy Rasmussen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,445
+29.01%
|
-
|
|
Jan 14
2022
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
35,161
+23.09%
|
-
|
|
Jan 14
2022
|
Michael J. Davidoff SVP, Payer Business |
BUY
Grant, award, or other acquisition
|
Direct |
35,161
+22.93%
|
-
|
|
Jan 14
2022
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
22,503
+23.47%
|
-
|
|
Jan 11
2022
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,750
+6.34%
|
$0
$0.84 P/Share
|
|
Jan 07
2022
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,270
+6.95%
|
$168,540
$2.03 P/Share
|
|
Jan 06
2022
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
30,950
+5.55%
|
$154,750
$5.82 P/Share
|